InvestorsHub Logo
Followers 34
Posts 3000
Boards Moderated 0
Alias Born 02/27/2016

Re: None

Monday, 10/16/2017 4:53:13 PM

Monday, October 16, 2017 4:53:13 PM

Post# of 461946
Once analysts see our trial design and understand we are handpicking our participants, they will realize our chances for success are extremely high.

If Missling sheds light on the trial design and it is accompanied by more data from part c that confirms our data and strategy, we go much much higher than 15 by year end.

Will the patients from the Rett and Parkinson's trials be picked in the same manner with many of the same inclusion and exclusion criteria? I'm assuming they will be. However, I don't believe the company has said it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News